Ani Pharmaceuticals (ANIP) Equity Ratio (2010 - 2026)

Ani Pharmaceuticals has disclosed Equity Ratio across 17 years of filings, most recently posting 0.4 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.4, down 3.76% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.4 (down 3.76% YoY), and the FY2025 annual result was 0.38, up 8923.12% from the prior year.
• Equity Ratio came in at 0.4 for Q1 2026 at Ani Pharmaceuticals, up from 0.38 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.58 in Q2 2024 to a low of 0.13 in Q3 2022.
• The 5-year median for Equity Ratio is 0.01 (2023), against an average of 0.2.
• Peak annual rise in Equity Ratio reached 24848936.85% in 2024, while the deepest fall reached 568.56% in 2024.
• Ani Pharmaceuticals' Equity Ratio stood at 0.53 in 2022, then sank by 100.0% to 0.0 in 2023, then surged by 188041.22% to 0.0 in 2024, then soared by 8923.12% to 0.38 in 2025, then rose by 5.34% to 0.4 in 2026.
• The last three Equity Ratio figures came in at 0.4 (Q1 2026), 0.38 (Q4 2025), and 0.36 (Q3 2025), per Business Quant data.